Brokerage Reports
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 441 - 460 ( 593 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2014 Results; Eylea Growing and Expect Praluent Approval
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Last Stretch for Alirocumab with BLA Priority Review Acceptance
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alirocumab Monthly Dosing Appears Efficient; Awaiting Regulatory Filings
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Elyea sBLA Application Accepted for FDA Priority Review
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dupilumab''s Breakthrough Designation in AD; SNY New Meds Launch Plans
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alirocumab Continues Positive Push Forward; Target to $461
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 25.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q14 Results; Growing Eylea Label and a Pipeline Running on All Pistons
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eylea Shows Superiority in Independent NIH-Sponsored Study
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another Approval for Eylea, This Time in BRVO; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00